Equine Performance Labs (EPL) is proud to announce the publication of a pivotal peer-reviewed study in BMC Medicine ("Cryopreserved equine umbilical cord tissue allograft characterization and biocompatibility in vivo in musculoskeletal tissues: a controlled study"), highlighting the safety, consistency, and biological innovation of its proprietary injectable allograft, equicent™ CTM, for equine musculoskeletal repair.^[1][2]

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250826041566/en/

Equine Performance Labs announces publication of landmark study in BMC Medicine demonstrating safety, consistency, and clinical promise of equicent™ CTM Umbilical Cord Allograft.

About The Study

The study, authored by industry leading equine researchers and clinicians, represents the first controlled, randomized, in vivo evaluation of an equine umbilical cord (UC) allograft. Key findings validate the product’s scientific and clinical impact:

• 2,645 proteins identified in each batch, with just 4.7% mean batch variation in proteins with high TSC — confirming unprecedented product consistency.
• Low inflammatory profile: High levels of IL-1ra and IL-10, low pro-inflammatory cytokines, and robust VEGF production.
• No adverse events: Demonstrated safety for intra-articular and intralesional use; all horses in controlled and clinical studies experienced no systemic side effects.

“We are the first to focus on a novel umbilical cord-derived equine product that is analogous to human WJ products. Our results will serve as an essential first step to characterize and determine in vivo safety of the first reported use of allogeneic WJ in equine, as well as serve as a pre-clinical study for humans. Within the limits of this study, UC was safe for injection into joints and ligaments in clinically normal horses. No adverse events were observed,” said Dr. Alicia L. Bertone, DVM, PhD, DACVS, lead author and independent equine clinical research consultant.

Heather Rogers, CEO of Equine Performance Labs, added:

“At EPL, our mission is ‘Horse First, Sport Second.’ Publication of this rigorous research in BMC Medicine reinforces our commitment to science, safety, and helping equine athletes recover naturally and comfortably. equicent™ CTM sets a new standard for biologics in the field.”

About equicent™ CTM

equicent™ CTM is an off-the-shelf, cryopreserved, micro-particulate UC tissue allograft, designed for precise and practical use in equine joints, tendons, and ligaments. Ethically and exclusively sourced through Coteau Grove Farms and processed in-house to human-grade standards, equicent™ CTM delivers unmatched protein-rich scaffolding and natural anti-inflammatory effects — without the variability of blood-derived or patient-dependent therapies.^[1]

About Equine Performance Labs

Founded on horse owner-driven innovation and world-class science, Equine Performance Labs develops advanced regenerative products to help horses heal, recover, and thrive. EPL’s proprietary tissue processing, closed donor herd, and published peer-reviewed research establish EPL as a credible leader in equine biologics.

The full study is available in the July 2025 issue of BMC Medicine. (Cryopreserved equine umbilical cord tissue allograft characterization and biocompatibility in vivo in musculoskeletal tissues: a controlled study | BMC Medicine | Full Text)

For product information, research details, and clinical queries, visit www.equineperformancelabs.com or contact info@equineperformancelabs.com

Citations:

: Bertone et al., BMC Medicine, 2025 (full manuscript & summary)^[1]

: PubMed record - PMID: 40702469^[2]

View source version on businesswire.com: https://www.businesswire.com/news/home/20250826041566/en/